off-label use

Off-label use refers to the practice of a physician prescribing a legally approved drug for a purpose not sanctioned by the country's regulatory authority, such as the U.S. Food and Drug Administration (FDA). This includes unapproved indications, patient populations, dosages, or routes of administration. While physicians have the discretion to prescribe drugs off-label based on their professional judgment, it is illegal for pharmaceutical companies to promote such uses under regulations like the Federal Food, Drug, and Cosmetic Act. This distinction is central to enterprise risk management; the practice is a medical decision, but its promotion by a company constitutes a severe compliance violation, leading to significant legal and financial penalties.

In enterprise risk management, addressing off-label use involves implementing robust compliance programs to prevent illegal promotion. Key steps include: 1) Establishing a clear governance policy that strictly prohibits off-label promotion and defines the separate roles of commercial and medical affairs teams. 2) Implementing mandatory, ongoing training for all relevant personnel on regulatory restrictions and the consequences of violations. 3) Deploying monitoring and auditing systems to review promotional materials, field-staff communications, and sales data for red flags. For example, global pharmaceutical firms have faced multi-billion dollar fines for such activities. A successful program can achieve over 99% compliance, virtually eliminating fine-related financial risks and ensuring successful regulatory audits.

Taiwanese enterprises face several key challenges: 1) Navigating regulatory gray areas, particularly distinguishing between permissible scientific exchange and illegal promotion during medical conferences. 2) Managing intense sales pressure that may incentivize staff to subtly promote off-label benefits. 3) Resource constraints in smaller biotech firms that lack dedicated compliance departments. To overcome these, companies should implement strict Standard Operating Procedures (SOPs) for medical information requests, realign sales incentives to reward compliant behavior, and leverage external expertise to build scalable compliance frameworks. Prioritizing a robust policy and training program can establish a foundational defense within three to six months.

Winners Consulting specializes in off-label use for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact